Clinical Trial Update: Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity [Phase 2]

View source ↗

Summary

Phase 2 trial investigating neoadjuvant docetaxel and carboplatin for anti-tumor activity in triple negative breast cancer; trial terminated with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Triple Negative Breast Neoplasms | Phase 2 | Status: TERMINATED | Results posted: 2022-11-07